UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism

Cancer research (Chicago, Ill.), 2017-03, Vol.77 (5), p.1188-1199

2017

Volltextzugriff (PDF)

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells

Haematologica (Roma), 2018-06, Vol.103 (6), p.939-948

2018

Volltextzugriff (PDF)

The Role of TAM Receptors in Bone

International journal of molecular sciences, 2023-12, Vol.25 (1), p.233

2023

Volltextzugriff (PDF)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR‐ABL Negative Myeloproliferative Neoplasms

HemaSphere, 2021-09, Vol.5 (9), p.e630-n/a

2021

Volltextzugriff (PDF)

1,25‐Dihydroxyvitamin D 3 administration to 6‐hydroxydopamine‐lesioned rats increases glial cell line‐derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum

Journal of neuroscience research, 2009-02, Vol.87 (3), p.723-732

2009

Volltextzugriff (PDF)

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.e243-e246

2018

Volltextzugriff (PDF)

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2

Communications biology, 2022-01, Vol.5 (1), p.97-97, Article 97

2022

Volltextzugriff (PDF)

Prolonged inhibition of intratumoral mast cells enhances efficacy of low-dose antiangiogenic therapy

International journal of cancer, 2024-08

2024

Volltextzugriff (PDF)

Sexual dimorphism in solid and hematological malignancies

Seminars in immunopathology, 2019-03, Vol.41 (2), p.251-263

2019

Volltextzugriff (PDF)

Macrophage–tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands

Cellular and molecular life sciences : CMLS, 2012-05, Vol.69 (9), p.1391-1414

2012

Volltextzugriff (PDF)

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

Expert review of hematology, 2015-04, Vol.8 (2), p.135-138

2015

Volltextzugriff (PDF)

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Blood, 2021-11, Vol.138 (Supplement 1), p.3410-3410

2021

Volltextzugriff (PDF)

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Blood, 2018-11, Vol.132 (Supplement 1), p.3063-3063

2018

Volltextzugriff (PDF)

Offspring born to influenza A virus infected pregnant mice show increased vulnerability to viral and bacterial infections in early life

Journal of reproductive immunology, 2023-09, Vol.159, p.104003, Article 104003

2023

Volltextzugriff (PDF)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Blood, 2018-11, Vol.132 (Supplement 1), p.2672-2672

2018

Volltextzugriff (PDF)

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Blood, 2018-11, Vol.132 (Supplement 1), p.1922-1922

2018

Volltextzugriff (PDF)

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7043-7043

2019

Volltextzugriff (PDF)

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Blood, 2017-12, Vol.130, p.1375-1375

2017

Volltextzugriff (PDF)

BET-Inhibition By JQ1 Promotes Proliferation and Self-Renewal Capacity of Hematopoietic Stem Cells

Blood, 2017-12, Vol.130, p.1900-1900

2017

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells

The Role of TAM Receptors in Bone

AXL Inhibition Represents a Novel Therapeutic Approach in BCR‐ABL Negative Myeloproliferative Neoplasms

1,25‐Dihydroxyvitamin D 3 administration to 6‐hydroxydopamine‐lesioned rats increases glial cell line‐derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2

Prolonged inhibition of intratumoral mast cells enhances efficacy of low-dose antiangiogenic therapy

Sexual dimorphism in solid and hematological malignancies

Macrophage–tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Offspring born to influenza A virus infected pregnant mice show increased vulnerability to viral and bacterial infections in early life

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

BET-Inhibition By JQ1 Promotes Proliferation and Self-Renewal Capacity of Hematopoietic Stem Cells

Aktive Filter

Suchergebnisse filtern